AbbVie Inc. $ABBV Shares Sold by Gabelli Funds LLC

Posted by Brenda Bartman on May 19th, 2026

Gabelli Funds LLC cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 19.6% in the fourth quarter, HoldingsChannel reports. The fund owned 81,213 shares of the company’s stock after selling 19,750 shares during the period. Gabelli Funds LLC’s holdings in AbbVie were worth $18,556,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ABBV. Wellington Management Group LLP raised its stake in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the period. Vanguard Group Inc. raised its stake in shares of AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after buying an additional 3,032,438 shares during the period. Raymond James Financial Inc. raised its stake in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the period. Alliancebernstein L.P. raised its stake in shares of AbbVie by 31.8% during the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company’s stock worth $1,685,918,000 after buying an additional 1,758,657 shares during the period. Finally, Amundi raised its stake in shares of AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of ABBV opened at $209.57 on Tuesday. AbbVie Inc. has a one year low of $180.25 and a one year high of $244.81. The stock has a market capitalization of $370.27 billion, a price-to-earnings ratio of 103.24, a PEG ratio of 0.73 and a beta of 0.32. The stock has a 50 day moving average price of $209.82 and a 200 day moving average price of $219.92.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the previous year, the business earned $2.46 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date was Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 340.89%.

Analyst Ratings Changes

Several brokerages have recently weighed in on ABBV. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Guggenheim reaffirmed a “buy” rating and set a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Morgan Stanley upped their target price on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Read Our Latest Analysis on ABBV

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by corporate insiders.

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.